Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Jul 11;14(7):e26751.
doi: 10.7759/cureus.26751. eCollection 2022 Jul.

The Role of Leptin in Systemic Lupus Erythematosus: Is It Still a Mystery?

Affiliations
Review

The Role of Leptin in Systemic Lupus Erythematosus: Is It Still a Mystery?

Nicole Villa et al. Cureus. .

Abstract

Systemic lupus erythematosus (SLE) is a chronic inflammatory connective tissue disease with varying clinical manifestations. Recent studies have proposed that leptin may be related to SLE development. This study aims to assess current information regarding the relationship between leptin and SLE. A systematic search was done using PubMed, Google Scholar, ScienceDirect, Epistemonikos, and Cochrane Library databases. Studies published in the English language in the last 10 years were selected based on predefined eligibility criteria. The quality of the studies was evaluated using the Newcastle-Ottawa Scale and the Assessment of Multiple Systematic Reviews 2 tool. A total of 12 studies were included in this systematic review. These included systematic reviews/meta-analyses, cross-sectional studies, and case-control studies. Based on the findings of this review, we conclude thatleptin is significantly elevated in SLE patients; however, it does not seem to correlate with disease activity. The exact mechanism of leptin in the pathogenesis of the disease remains unknown and further research is needed regarding this aspect.

Keywords: leptin; leptin receptor; sle; systematic review; systemic lupus erythematosus.

PubMed Disclaimer

Conflict of interest statement

The authors have declared that no competing interests exist.

Figures

Figure 1
Figure 1. PRISMA flowchart of the study search selection.
PRISMA: Preferred Reporting Items for Systematic Reviews and Meta-Analyses

References

    1. One year in review 2022: systemic lupus erythematosus. Zucchi D, Elefante E, Schilirò D, Signorini V, Trentin F, Bortoluzzi A, Tani C. Clin Exp Rheumatol. 2022;40:4–14. - PubMed
    1. Systemic lupus erythematosus: the devastatingly deceptive disease. Felz M, Wickham MB. https://www.mdedge.com/clinicianreviews/article/110888/immunology/system... Clin Rev. 2016;26:38–46.
    1. Incidence rates of systemic lupus erythematosus in the USA: estimates from a meta-analysis of the Centers for Disease Control and Prevention national lupus registries. Izmirly PM, Ferucci ED, Somers EC, et al. Lupus Sci Med. 2021;8:0. - PMC - PubMed
    1. Circulating leptin level, soluble leptin receptor level and their gene polymorphism in patients with systemic lupus erythematosus: a systematic review and meta-analysis. Yuan Q, Zhang L, Tian Y, Li W, Li X, Lu Z. https://pubmed.ncbi.nlm.nih.gov/32662402/ Clin Exp Rheumatol. 2020;38:1238–1246. - PubMed
    1. Immunological pathogenesis and treatment of systemic lupus erythematosus. Pan L, Lu MP, Wang JH, Xu M, Yang SR. World J Pediatr. 2020;16:19–30. - PMC - PubMed

LinkOut - more resources